Dermatomyositis: current and future treatments

Vleugels, Ruth Ann; Callen, Jeffrey P.

doi:10.1586/edm.09.52

Cited by 7 publications

(9 citation statements)

References 125 publications

(110 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Midday sun should also be avoided if possible, as well as tanning beds. Consideration should be given to vitamin D status and possible supplementation given the degree of photoprotection required in DM .…”

Section: Photoprotectionmentioning

confidence: 99%

“…Notably, they exert immunomodulatory, anti‐inflammatory, and antiproliferative effects, in addition to having photoprotective properties . Although they can be effective in up to 75% of cases of cutaneous DM, they do not benefit muscle disease . Generally considered among the safest forms of systemic therapy available for connective tissue diseases, antimalarials are often used as first‐line systemic therapy in the management algorithm of cutaneous DM.…”

Section: Antimalarialsmentioning

confidence: 99%

“…Several experts recommend switching from HCQ to CQ and/or adding quinacrine 100–200 mg daily to either HCQ or CQ if patients fail to respond adequately . In a retrospective case series evaluating cutaneous outcome in 17 patients with cutaneous DM , the authors found that seven patients responded to antimalarial therapy alone and two were maintained on antimalarials after additional treatment with methotrexate (MTX) and/or prednisone.…”

Section: Antimalarialsmentioning

confidence: 99%

“…Some experts suggest short courses of prednisone 1 mg/kg/day tapered over 2–3 months for particularly symptomatic skin DM, especially while awaiting the onset of other slower‐acting systemic agents . Other experts prefer to avoid systemic steroids for skin‐limited disease given that the doses required to effectively treat cutaneous DM frequently result in steroid‐related side effects, and rather choose to initiate steroid‐sparing agents earlier in the disease course of cutaneous DM . In JDM, both oral prednisone and intravenous methylprednisolone have been studied, particularly at the onset of disease, and efficacy has been demonstrated mainly for muscle disease as well as for prevention of calcinosis cutis .…”

Section: Systemic Corticosteroidsmentioning

confidence: 99%

“…From the data available, it seems that patients with CADM are also at risk for internal malignancy, although this risk may be less than for DM . There is current debate in the literature regarding the necessity of aggressive management of cutaneous disease to prevent the occurrence of myositis or systemic involvement .…”

mentioning

confidence: 99%

See 4 more Smart Citations

Management of cutaneous dermatomyositis

Lam

Vleugels

2012

Dermatol Ther

Self Cite

View full text Add to dashboard Cite

Dermatomyositis (DM) is traditionally classified as an idiopathic inflammatory myopathy distinguished by muscle weakness and characteristic cutaneous findings. Patients presenting with the skin manifestations in the absence of clinical evidence of muscle weakness are categorized as clinically amyopathic DM. The symptoms associated with the cutaneous findings can be particularly debilitating, and a discordant response to therapy exists between muscle and skin disease. Various therapeutic agents and treatment approaches have been described, both for the cutaneous and extracutaneous manifestations; however, a paucity of controlled studies in this disease leads to limitations in interpreting the available data. In this review, emphasis is placed specifically on summarizing the current literature regarding management of cutaneous DM. In addition, an algorithmic approach to treatment of skin disease is presented.

show abstract

Section: Photoprotectionmentioning

confidence: 99%

Section: Antimalarialsmentioning

confidence: 99%

Section: Antimalarialsmentioning

confidence: 99%

Section: Systemic Corticosteroidsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Management of cutaneous dermatomyositis

Lam

Vleugels

2012

Dermatol Ther

Self Cite

View full text Add to dashboard Cite

show abstract

Anti‐nuclear matrix protein 2 antibody‐positive amyopathic dermatomyositis presenting in a patient with prostate cancer: A case report

Shan,

Gupta,

Ortega‐Loayza

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageNuclear matrix protein (NXP‐2) positive amyopathic dermatomyositis (DM) may present without classic symptoms like muscle weakness, dysphagia, and edema, and mimic conditions like cutaneous lupus. Given DM's association with malignancy and interstitial lung disease, prompt and accurate diagnosis is important. Testing for myositis‐specific antibodies aids diagnosis in ambiguous cases.

show abstract